Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
IPO Year:
Exchange: NASDAQ
Website: apolloendo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/4/2023 | $10.00 | Buy → Hold | Stifel |
| 11/30/2022 | $14.00 → $10.00 | Buy → Hold | Lake Street |
| 2/23/2022 | $12.00 → $10.00 | Buy | Stifel |
| 12/15/2021 | $13.00 | Outperform | Cowen & Co. |
| 12/9/2021 | $12.00 | Buy | Stifel |
| 9/9/2021 | $15.00 | Overweight | Stephens |
K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w
Veteran Brings 30 Years of Multinational Healthcare Leadership ExperienceAUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products."Jeannette Bankes is a seasoned healthcare executive and board member known for applying her tremendous insight, experi
Veteran Leader Brings 25 Years of Global Medical Device ExperienceAUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022."At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss. We understand that developing products and procedures is only one component, and that facilitating patient access is a key element to successfully developing these markets," said Chas McKhann, president and CEO of A
Veteran Executive Brings 30 Years of Financial and Operational Leadership ExperienceAUSTIN, TX / ACCESSWIRE / July 16, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Jeffrey G. Black as Chief Financial Officer. Mr. Black has served as Chief Financial Officer for a variety of publicly-traded companies in the medical device, diagnostics, life sciences, technology and industrial biotech industries."Jeff is a collaborative leader who builds and leads strong teams and has highly relevant experience for a company at our stage of growth," said Chas McKhann, p
15-12G - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13D/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi
AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only op
AUSTIN, TX / ACCESSWIRE / April 13, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the first quarter ended March 31, 2022 on Tuesday, May 3, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only opti
AUSTIN, TX / ACCESSWIRE / February 10, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the fourth quarter and full year ended December 31, 2021 on Tuesday, February 22, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apollo
Fourth quarter 2021 revenue grew 25% over 2020AUSTIN, TX / ACCESSWIRE / January 10, 2022 / Apollo Endosurgery, Inc. ("Apollo" or the "Company") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2021.Preliminary, Unaudited 2021 Revenue Quarter EndedDecember 31, 2021Year EndedDecember 31, 2021Total revenue$16.1 million to $16.3 million$62.9 million to $63.1 millionPreliminary, unaudited full year 2021 revenue increased approximately 50% compared to 2020. In addition, preliminary, unaudited fourth quarter 2021 revenue grew app
AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights.Third Quarter 2021 Selected Financial ResultsTotal revenue of $16.4 million, an increase of 28% compared to the third quarter of 2020Endoscopic Suturing System (ESS) revenue increased 34% and Intragastric Balloon (IGB) revenue increased 21% compared to the third quarter of 2020Gross margin of 56%Pro forma cash of $98.3 million, including net proceeds from October 2021 follow-on offeringRecent
AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2021 on Monday, November 1, 2021 after the market closes.In conjunction with the release, Apollo will host a live webcast audio call with slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only
Revenue expected between $16.0 million and $16.4 millionThird consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30%Submitted a De Novo 510(k) Classification Request to FDA for Apollo ESG™ for weight loss and Apollo REVISE™ for prior bariatric surgery revisionsPrincipal investigators expected to present primary efficacy and safety endpoints from MERIT study in late OctoberAUSTIN, TX / ACCESSWIRE / October 7, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today preliminary unaudited financial results and corporate updates for the third quarter ended
AUSTIN, TX / ACCESSWIRE / August 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021.HighlightsAchieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a new revenue record for the Company*Increased Endoscopic Suturing System (ESS) revenue 23% and Intragastric Balloon (IGB) revenue 16% on a sequential basis compared to the first quarter of 2021Realized gross margin of 55% on favorable product mixContinued rollout of X-Tack™ with now more than 120 active sites, demon
Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00
Lake Street downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00 from $14.00 previously
Stifel reiterated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $10.00 from $12.00 previously
Cowen & Co. initiated coverage of Apollo Endosurgery with a rating of Outperform and set a new price target of $13.00
Stifel initiated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $12.00
Stephens initiated coverage of Apollo Endosurgery with a rating of Overweight and set a new price target of $15.00
Piper Sandler reiterated coverage of Apollo Endosurgery with a rating of Overweight and set a new price target of $11.00 from $9.00 previously
Lake Street initiated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $12.00
MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th
MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric DevicesAUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.(3) These milestones come only months after Apollo received FDA
Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (NASDAQ:APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.1 The Apollo Endosurgery product portfolio includes devices used during endoluminal surgery (ELS) procedures to close gastrointestinal defects, manage gastrointestinal co
OverStitch has new indications for use statement under CE-Mark, including indications for defect closure, stent fixation, endoscopic sleeve gastroplasty and transoral outlet reductionAUSTIN, TX / ACCESSWIRE / November 21, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has successfully transitioned its legacy products to CE Mark under the European Medical Device Regulation (MDR). The new certificates were issued by British Standards Institute and were received by the company on November 17, 2022. The certificates are valid for five years.Importantly, as part
AUSTIN, TX / ACCESSWIRE / November 7, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that its senior management team will host investor meetings at four investor conference events during November and December 2022.Event: Stifel 2022 Healthcare ConferenceDate: Wednesday, November 16, 2022Presentation: 2:25 p.m. Eastern Time; 1x1 meetings availableLocation: Lotte New York Palace Hotel, New York CityWebcast: www.apolloendo.comEvent: 13th Annual Craig-Hallum Alpha Select ConferenceDate: Thursday, November 17, 2022Presentation: 1x1 meetings availableLocation: Sheraton Ne
Grew global revenue 20% GAAP, 24% in constant currencyReceived FDA authorization for Apollo ESGTM and Apollo REVISETM systems for treating patients with obesityAUSTIN, TX / ACCESSWIRE / November 1, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2022 and recent corporate highlights.Third Quarter 2022 Selected Financial Results(Numbers in millions, except percentages) Quarter Ended September 30, 2022 Nine Months EndedSeptember 30, 2022 Revenue $19.6 $55.5 Gross margin 54.9% 55.9%Operating expenses $17.0 $51.2
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi
K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w
Grew global revenue 16% (20% in constant currency) as adoption increased across all product linesSecured FDA marketing authorization for Apollo ESGTM and Apollo REVISETMAUSTIN, TX / ACCESSWIRE / August 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2022 and recent corporate highlights.Second Quarter 2022 Selected Financial Results(Numbers in millions, except percentages) Quarter Ended June 30, 2022 Six Months EndedJune 30, 2022 Revenue $19.3 $36.0 Gross margin 56.8% 56.5%Operating expenses $17.5 $34.2 Non-GA
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)